ArticleHealthcare (Basel, Switzerland)2022
Fighting Cancer around the World: A Framework for Action.
Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Mushrooms as potent autophagy modulators in cancer therapy: Current evidence and therapeutic prospects.Cancer pathogenesis and therapy · 2026Review
- Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology.Biomolecules · 2026Review
- Beyond the Cure: Unveiling the Silent Struggles of Breast Cancer Survivors in Hong Kong.Healthcare (Basel, Switzerland) · 2026Article
- Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.International journal of nanomedicine · 2026Review
- Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy.International journal of pharmaceutics: X · 2025Review
- Beyond COL1A1::PDGFB: Rare fusions and their clinical implications in dermatofibrosarcoma protuberans.World journal of clinical cases · 2025Article
- Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Driving the future of value-based healthcare in the Gulf Cooperation Council: a roadmap for achieving sustainable access to specialty pharmaceuticals.Frontiers in public health · 2025Article
- Efficient and Accurate Brain Tumor Classification Using Hybrid MobileNetV2-Support Vector Machine for Magnetic Resonance Imaging Diagnostics in Neoplasms.Brain sciences · 2024Article
- Cancer patients' return-to-work adaptation experience and coping resources: a grounded theory study.BMC nursing · 2023Article
- Landscape of germlineFrontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tackling cancer is a major challenge right on the global level. Europe is only the tip of an iceberg of cancer around the world. Prosperous developed countries share the same problems besetting Europe-and the countries and regions with fewer resources and less propitious conditions are in many cases struggling often heroically against a growing tide of disease. This paper offers a view on these geographically wider, but essentially similar, challenges, and on the prospects for and barriers to better results in this ceaseless battle. A series of panels have been organized by the European Alliance for Personalised Medicine (EAPM) to identify different aspects of cancer care around the globe. There is significant diversity in key issues such as NGS, RWE, molecular diagnostics, and reimbursement in different regions. In all, it leads to disparities in access and diagnostics, patients' engagement, and efforts for a better understanding of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.